Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives

• Main Authors: Francesco Chiarelli, Daniele Di Marzio
• Format: Article
• Language: English
• Published: Dove Medical Press 2008-04-01
• Series: Vascular Health and Risk Management
• Online Access: https://www.dovepress.com/peroxisome-proliferator-activated-receptor-gamma-agonists-and-diabetes-peer-reviewed-article-VHRM

Francesco Chiarelli, Daniele Di MarzioDepartment of Pediatrics, University of Chieti, ItalyAbstract: Since their initial availability in 1997, the thiazolidinediones (TZDs) have become one of the most commonly prescribed classes of medications for type 2 diabetes. In addition to glucose control, the TZDs have a number of pleiotropic effects on myriad traditional and non-traditional risk factors for diabetes. TZDs may benefit cardiovascular parameters, such as lipids, blood pressure, inflammatory biomarkers, endothelial function and fibrinolytic state. In this review, we summarise the experimental, preclinical and clinical data regarding the effects of the TZDs in conditions for which they are indicated and discuss their potential in the treatment of other conditions.Keywords: PPARγ, thiazolidinediones, rosiglitazone, pioglitazone, troglitazone